Please assess the completion status of the following clinical trial:

Trial Title: Drug Interaction Study Between Dorzagliatin and Sitagliptin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects diagnosed with T2DM within at least 3 months prior to screening~2. Male and/or female subjects between the ages of 30 and 65 years, inclusive;~3. Body Mass Index (BMI) of 19 to 38 kg/m2, inclusive;~4. Fasting C-peptide test result \>0.3 nmol/L (\>0.90 ng/mL);~5. HbA1c ≥7% and ≤10.5%;~Exclusion Criteria:~1. Fasting blood glucose at screening or Day -1 ≤110 or ≥270 mg/dL;~2. Type 1 diabetes mellitus;~3. Reported incidence of severe or serious hypoglycemia within 3 months prior to screening;~4. Known contraindications to sitagliptin;~5. Clinically significant gastrointestinal disorder;~6. History or symptoms of clinically significant cardiovascular disease within one year prior to screening;~7. History of more than three urinary tract infections and/or more than three genital fungal infections in the last 12 months;~8. Reported history of clinically significant central nervous system disease;~9. Reported history of liver disease;~10. Reported history of clinically significant renal disease;~11. Estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m2;~12. Acute or chronic metabolic acidosis, including diabetic ketoacidosis;~13. Known or suspected malignancy;~14. Any reported hypersensitivity or intolerance to sitagliptin;~15. Antidiabetic treatment with insulin, sulfonylureas, thiazolidinediones or GLP-1 agonist within 3 months prior to screening;~16. Systolic blood pressure \<90 or \>160 mmHg or diastolic blood pressure \<60 or \>100 mmHg at screening;~17. A hospital admission or major surgery within 90 days prior to screening;~18. Uncontrolled hypertriglyceridemia \>500 mg/dL;~19. Positive blood screen for HIV, hHBsAg, or hepatitis C antibody;~20. Positive pregnancy test result;~21. Female is breast-feeding or planning to become pregnant;~22. Treated with any investigational drugs within 6 weeks prior to screening;~23. Reported history of prescription drug abuse;~24. Reported history of alcohol abuse;~25. Reported history of donation or or acute loss of blood during the 90 days prior to screening;

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sequential arm ABC (Type: EXPERIMENTAL): A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).